Diabetes mellitus and options for early prevention of heart failure

Czech version

Authors: Andrej Dukát; Peter Jackuliak; Juraj Payer
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Diab Obez 2023; 23(45): 18-21
Category: Reviews

Overview

Despite often clinical manifestation of chronic heart failure among patients with diabetes mellitus, had not been carefully targeted yet. Even one fifth of patients with diabetes mellitus manifest heart failure will develop to an unfavorable prognostic outcome. It is 3 to 4 times more in the group of both types of diabetes mellitus comparing to nondiabetic group of patients. Thus diabetic patients represent prognostically high risk population, where heart failure may be even the first ever cardiovascular complication. For this reason experts of the American Diabetes Association four months ago brought their new guideline for early diagnosis and treatment of these patients for the prevention of this severe complication.

Keywords:

prevention – diabetes mellitus – chronic heart failure

Sources

1. Popbusui R, Januzzi JL, Bruemmer D et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetic Association. Diabetes Care 2022; 45(7): 1670–1690. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0014>.

2. [American Diabetes Association. Professional Practice Committee]. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022: 45(Suppl 1): S144-S174. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-S010>.

3. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes 2022. Diabetes Care 2022: 45(Suppl 1): S1-S2. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-Sint>.

4. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res 2019; 124(1): 121–141. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.118.311371>.

5. Leung AA, Eurich DT, Lamb DA et al. Risk of heart failure in patients with recent-onset type 2 diabetes:population-based cohort study. J Card Fail 2009; 15(2): 152–157. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2008.10.004>.

6. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29–34. Dostupné z DOI: <http://dx.doi.org/10.1016/0002–9149(74)90089–7>.

7. He J, Ogden LG, Bazzano LA et al. Risk factors for congestive heart failure in US men and women. NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161(7): 996–1002. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.161.7.996>.

8. Brunvand L, Fugelseth D, Stensaeth KH et al. Early reduced myocardial diastolic function in children and adolescents with type1 diabetes mellitus:a population-based study. BMC Cardiovasc Disord 2016; 16: 103. Dostupné z DOI: <http://dx.doi.org/10.1186/s12872–016–0288–1>.

9. Goncalvesová E (ed) et al. Zlyhávanie srdca. Pro Litera: Bratislava 2015. ISBN 978–80–89668–03–8.

10. Park JJ. Epidemiology, Pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J 2021; 45(2): 146–157. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2020.0282>.

11. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57(4): 660–671. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–014–3171–6>.

12. Bozkurt B, Coats AJ, Tsutsui H et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021; S1071–9164(21)00050–6. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2021.01.022>.

13. Birtcher KK, Allen LA, Anderson JL et al. 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Petient-Centered Car: A Report of the American College of Cardiology Solution Set Oversight Committeee. J Am Coll Cardiol; 81(3): 292–317. Dostupné z DOI: <https://doi.org/10.1016/j.jacc.2022.08.754>.

14. Dukát A (ed), Gajdošík J, Payer J et al (eds). Epidemiológia srdcového zlyhávania na Slovensku. Facta Medica: Brno 2017. ISBN 978–80–88056–04–1.

15. Pandey A, Vaduganathan M, Patel KV et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail 2021; 9(3): 215–223. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2020.10.013>.

16. Jarolim P, White WB, Cannon CP et al. Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial. Diabetes Care 2018; 41(7): 1510–1515. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0109>.

17. Dukát A, Payer J, Kyselovič J et al. Čo priniesol nový konsensus odborných spoločností pre pacientov s diabetes mellitus s komplikáciou vývoja do srdcového zlyhávania. Lek Obzor 2022: 71(12): 526–533.

18. Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013; 1832(12): 2442–2450. Dostupné z DOI: <http://doi 10.1016/j.bbadis.2012.12.014>.

19. 19.Braunwald E. Heart Failure. JACC Heart Fail 2013; 1(1):1–20. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2012.10.002>.

20. Januzzi JL, Rehman SU, Mohammed AA et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58(18): 1881–1889. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.03.072>.

21. Fonarow GC, Peacock WF, Phillips CO et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49(19): 1943–1950. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.02.037>.

22. Maisel AS, McCord J, Nowak RM et al. Bedside B-type natriuretic petide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol 2003; 41(11): 2010–2017. Dostupné z DOI: <http://dx.doi.org/10.1016/s0735–1097(03)00405–4>.

23. Dukát A, Payer J, Šimko F. GDF-15: Nový prediktívny biomarker pre diabetes mellitus 2. typu v klinickej praxi. Diab Obez 2020; 20(40): 7–11.

24. Dukát A, Payer J, Gajdošík J et al. Miesto biomarkerov pri rutínnom manažmente pacientov s chronickým srdcovým zlyhávaním a ich diagnostický a prognostický význam. Lek Obzor 2020: 69(7–8): 261–263.

25. Huelsmann M. NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02817360>.